Fiore L D, Brophy M T, Ferguson R E, Shannon C, Turek S J, Pierce-Murray K, Ajjarapu S, Huang G D, Lee Cse, Lavori P W
VA Boston Healthcare System, Boston, Massachusetts, USA.
Clin Pharmacol Ther. 2017 May;101(5):586-589. doi: 10.1002/cpt.660. Epub 2017 Mar 20.
Cancer genomic research reveals that a similar cancer clinical phenotype (e.g., non-small cell lung cancer) can arise from various mutations in tumor DNA. Thus, organ of origin is not a definitive classification. Further, targeted therapy for cancer patients (precision oncology) capitalizes on knowledge of individual patient mutational status to deliver treatment directed against the protein products of these mutations with the goal of reducing toxicity and enhancing efficacy relative to traditional nontargeted chemotherapy.
癌症基因组研究表明,相似的癌症临床表型(如非小细胞肺癌)可由肿瘤DNA中的各种突变产生。因此,起源器官并非一种明确的分类方式。此外,癌症患者的靶向治疗(精准肿瘤学)利用个体患者的突变状态知识,针对这些突变的蛋白质产物进行治疗,目的是相对于传统的非靶向化疗降低毒性并提高疗效。